Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
about
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Efficacy of a Novel Sigma-1 Re ...... lled Phase IIa Clinical Trial.
@en
Efficacy of a Novel Sigma-1 Re ...... lled Phase IIa Clinical Trial.
@nl
type
label
Efficacy of a Novel Sigma-1 Re ...... lled Phase IIa Clinical Trial.
@en
Efficacy of a Novel Sigma-1 Re ...... lled Phase IIa Clinical Trial.
@nl
prefLabel
Efficacy of a Novel Sigma-1 Re ...... lled Phase IIa Clinical Trial.
@en
Efficacy of a Novel Sigma-1 Re ...... lled Phase IIa Clinical Trial.
@nl
P2093
P2860
P50
P1433
P1476
Efficacy of a Novel Sigma-1 Re ...... olled Phase IIa Clinical Trial
@en
P2093
Andreas A Argyriou
Anna Vaqué
Carlos Plata-Salamán
Chiara Briani
Cristina Nadal
Cristina Santos
Haralabos P Kalofonos
Jesús Villoria
Mariano Sust
Roser Velasco
P2860
P2888
P304
P356
10.1007/S13311-017-0572-5
P577
2018-01-01T00:00:00Z